RA affects about 1 percent of the world's population,(4) including more than two million adults in the United States.(1) In this population, ORENCIA(R) (abatacept) is indicated to treat adults with moderately to severely active RA who have had an inadequate response to one or more DMARDs.(5) The condition is more common in women than in men, who account for 75 percent of patients diagnosed with RA.(1)
About the Survey
The survey is based on 340 telephone interviews conducted among Americans living with rheumatoid arthritis who were 18 years of age and older. Of this group, 128 interviews were completed with people who have rheumatoid arthritis and who have experienced an inadequate response to some biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs).(2) The results reflected in this release represent this patient population of 128 people. All interviews were conducted in March, April and May 2007.(2) GfK Roper Public Affairs & Media, part of GfK Custom Research North America, conducted the survey on behalf of Bristol-Myers Squibb.
About ORENCIA(R) (abatacept)
ORENCIA is a prescription medicine that is used to treat adults with moderate-to-severe rheumatoid arthritis (RA) who have not been helped enough by other medicines for RA. A doctor may consider treatment with ORENCIA because the patient's disease is still active even though they may have tried other treatments. ORENCIA can be used alone or with other agents. ORENCIA should not be taken with biologic medications for RA such as Enbrel(R), Humira(R), Remicade(R), or Kineret(R).
Dosing and Administration
ORENCIA is administered by a healthcare professional as a 30-min
'/>"/>
| SOURCE Bristol-Myers Squibb Copyright©2008 PR Newswire. All rights reserved |